Caparrós-MartÃn, J.A.; Maher, P.; Ward, N.C.; Saladié, M.; Agudelo-Romero, P.; Stick, S.M.; Chan, D.C.; Watts, G.F.; O’Gara, F.
An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a). Microorganisms 2024, 12, 170.
https://doi.org/10.3390/microorganisms12010170
AMA Style
Caparrós-MartÃn JA, Maher P, Ward NC, Saladié M, Agudelo-Romero P, Stick SM, Chan DC, Watts GF, O’Gara F.
An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a). Microorganisms. 2024; 12(1):170.
https://doi.org/10.3390/microorganisms12010170
Chicago/Turabian Style
Caparrós-MartÃn, Jose A., Patrice Maher, Natalie C. Ward, Montserrat Saladié, Patricia Agudelo-Romero, Stephen M. Stick, Dick C. Chan, Gerald F. Watts, and Fergal O’Gara.
2024. "An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)" Microorganisms 12, no. 1: 170.
https://doi.org/10.3390/microorganisms12010170
APA Style
Caparrós-MartÃn, J. A., Maher, P., Ward, N. C., Saladié, M., Agudelo-Romero, P., Stick, S. M., Chan, D. C., Watts, G. F., & O’Gara, F.
(2024). An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a). Microorganisms, 12(1), 170.
https://doi.org/10.3390/microorganisms12010170
